Texas Permanent School Fund reduced its position in Allergan PLC. (NYSE:AGN) by 3.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 94,369 shares of the company’s stock after selling 3,578 shares during the period. Texas Permanent School Fund’s holdings in Allergan PLC. were worth $22,940,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Ingalls & Snyder LLC increased its stake in Allergan PLC. by 4.0% in the second quarter. Ingalls & Snyder LLC now owns 1,304 shares of the company’s stock worth $317,000 after buying an additional 50 shares during the last quarter. Barnett & Company Inc. increased its stake in Allergan PLC. by 168.4% in the second quarter. Barnett & Company Inc. now owns 3,969 shares of the company’s stock worth $965,000 after buying an additional 2,490 shares during the last quarter. Supplemental Annuity Collective Trust of NJ increased its stake in Allergan PLC. by 122.2% in the second quarter. Supplemental Annuity Collective Trust of NJ now owns 6,000 shares of the company’s stock worth $1,459,000 after buying an additional 3,300 shares during the last quarter. Cadence Bank NA increased its stake in Allergan PLC. by 12.0% in the second quarter. Cadence Bank NA now owns 1,643 shares of the company’s stock worth $399,000 after buying an additional 176 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D increased its stake in Allergan PLC. by 28.3% in the second quarter. State of New Jersey Common Pension Fund D now owns 385,702 shares of the company’s stock worth $93,760,000 after buying an additional 85,000 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Shares of Allergan PLC. (AGN) opened at 221.81 on Monday. The stock has a market capitalization of $74.15 billion, a PE ratio of 6.76 and a beta of 1.16. The stock has a 50 day moving average price of $240.49 and a 200-day moving average price of $238.48. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. During the same quarter in the previous year, the company earned $3.35 EPS. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. On average, analysts forecast that Allergan PLC. will post $16.27 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 1.26%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is presently 9.95%.

COPYRIGHT VIOLATION NOTICE: “Texas Permanent School Fund Sells 3,578 Shares of Allergan PLC. (AGN)” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://theolympiareport.com/2017/08/28/texas-permanent-school-fund-sells-3578-shares-of-allergan-plc-agn.html.

A number of research firms recently weighed in on AGN. BidaskClub downgraded Allergan PLC. from a “sell” rating to a “strong sell” rating in a research report on Friday. Cantor Fitzgerald restated a “hold” rating on shares of Allergan PLC. in a research report on Tuesday, August 22nd. Argus restated a “buy” rating and issued a $280.00 target price on shares of Allergan PLC. in a research report on Monday, August 14th. UBS AG restated an “outperform” rating and issued a $275.00 target price on shares of Allergan PLC. in a research report on Wednesday, August 9th. Finally, Deutsche Bank AG restated a “buy” rating and issued a $278.00 target price (up previously from $273.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $275.49.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.